Amoytop Biotech
Xiamen, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese biopharma company developing and commercializing long-acting recombinant protein drugs for hepatitis, oncology, and immunotherapy.
Infectious DiseaseOncologyImmunologyEndocrinology
Technology Platform
Specializes in recombinant protein expression and long-acting formulation using PEGylation technology, notably a proprietary Y-shaped 40-kDa PEGylation platform.
Opportunities
Significant opportunity in the large Chinese CHB patient population for a functional cure, and expansion of its long-acting biologic portfolio in oncology supportive care and other cytokine-driven diseases.
Risk Factors
Clinical and regulatory risks associated with its innovative CHB pipeline; competition in the marketed biosimilar and long-acting supportive care drug markets in China.
Competitive Landscape
Competes with large domestic and multinational pharma companies in the interferon and granulocyte colony-stimulating factor (G-CSF) markets. Differentiates through a specialized focus on cytokine PEGylation and a strategic R&D push in hepatitis B cure.